Boston Partners Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Key Points

• Boston Partners has reduced its stake in Johnson & Johnson by 22.3%, selling 503,772 shares during the 1st quarter, leaving them with 1,759,295 shares valued at approximately $291.7 million.
• As of its most recent filings, 69.55% of Johnson & Johnson's stock is owned by hedge funds and institutional investors, indicating strong institutional interest in the company.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, reflecting an annualized dividend of $5.20, with a dividend yield of 3.0% and a payout ratio of 55.61%.

Boston Partners reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 22.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,759,295 shares of the company's stock after selling 503,772 shares during the period. Boston Partners owned 0.07% of Johnson & Johnson worth $291,695,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Lantz Financial LLC increased its position in Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after purchasing an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $453,000. Joel Isaacson & Co. LLC increased its position in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after purchasing an additional 2,526 shares in the last quarter. State of Wyoming increased its position in Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares in the last quarter. Finally, Range Financial Group LLC increased its position in Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after purchasing an additional 2,529 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $172.79 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market cap of $416.14 billion, a P/E ratio of 18.48, a P/E/G ratio of 2.21 and a beta of 0.41. The business's fifty day moving average is $160.00 and its two-hundred day moving average is $157.90. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $174.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the firm earned $2.82 earnings per share. The business's revenue was up 5.8% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on JNJ shares. Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Bank of America increased their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.